Prostate specific antigen (PSA) is a blood-based biomarker that can be used in the screening of patients for PC detection, in the surveillance of patients following diagnosis, to assess the risk of PC recurrence, and for monitoring treatment responses. Here, KLK3 is linked to pachyonychia congenita.